Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 5/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6254501 | 0.88 | ELANE (0.50) | ELANEPPARAL3MBTL1ATMTDP1 | |
| SCHEMBL6258561 | 0.84 | ALDH1A1 (0.49) | PPARAL3MBTL1TDP1 | |
| SCHEMBL27267828 | 0.82 | MEN1 (0.45) | PPARAL3MBTL1 | |
| SCHEMBL24850203 | 0.81 | L3MBTL1 (0.51) | PPARGPPARAL3MBTL1 | |
| SCHEMBL6716190 | 0.80 | PPARA (0.57) | ELANEPPARGPPARA | |
| SCHEMBL6260000 | 0.80 | CES1 (0.42) | ELANEPPARA | |
| SCHEMBL11120603 | 0.80 | PPARA (0.49) | PPARGPPARAL3MBTL1 | |
| SCHEMBL6254689 | 0.79 | ELANE (0.48) | ELANEPPARAL3MBTL1ATMTDP1 | |
| SCHEMBL6254687 | 0.79 | ELANE (0.48) | ELANEPPARAL3MBTL1ATMTDP1 | |
| SCHEMBL6257018 | 0.78 | ELANE (0.71) | ELANEPPARAL3MBTL1ATMTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005068410-A1 | ETHER COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2005-07-28 | — | — | WO | claimed |
| US-20040192771-A1 | Ether compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. | 2004-09-30 | — | — | US | claimed |
| JP-2004529069-A | — | — | 2004-09-24 | — | — | JP | claimed |
| EP-1351916-A2 | ETHER COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | Esperion Therapeutics Inc. (US) | 2003-10-15 | — | — | EP | claimed |
| US-20030018013-A1 | Ether compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. | 2003-01-23 | — | — | US | claimed |
| WO-2002030863-A2 | ETHER COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2002-04-18 | — | — | WO | claimed |
| US-6713507-B2 | CARDIOVASCULAR DISORDERS; ANTILIPEMIC AGENTS; ALZHEIMER'S DISEASE | ESPERION THERAPEUTICS, INC. | 2004-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018013-A1 | Ether compounds and compositions for cholesterol management and related uses | GPR119, PNLIP, NR1H2 | ELANE 195/4885PPARG 10/4885PPARA 19/4885 |
| US-20040192771-A1 | Ether compounds and compositions for cholesterol management and related uses | GPR119, PNLIP, NR1H2 | ELANE 195/4885PPARG 10/4885PPARA 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.